About Flavia Castelino, MD

Dr. Flavia Castelino is the Director of the Scleroderma Program at Massachusetts General Hospital and an Assistant Professor of Medicine at Harvard Medical School. She is a board-certified physician in the Division of Rheumatology and she specializes in the treatment of scleroderma and connective tissue disease-associated interstitial lung disease (CTD-ILD). 

Dr. Castelino founded the MGH Scleroderma Program with a focus on providing outstanding comprehensive care for patients with scleroderma and related conditions. The MGH Scleroderma Program maintains a clinical registry and biorepository of patients with scleroderma to perform clinical and translational research. Dr. Castelino is additionally a principal investigator on several clinical trials evaluating novel therapies for the treatment of scleroderma.

She has many active collaborations nationally and internationally and is a member of the Executive Committee of the CONQUER Registry, a multi-center US based registry of scleroderma patients. She has served on several committees within the American College of Rheumatology, and is a member of the Scleroderma Clinical Trials Consortium. She additionally serves as a reviewer for several medical journals including the Journal of the American Medical Association (JAMA), Arthritis and Rheumatology, Arthritis Care and Research.

Dr. Castelino has been invited to speak nationally and internationally on scleroderma and related conditions, including CTD-ILD. She is the recipient of numerous awards including the American College of Rheumatology (ACR) Distinguished Fellow Award, the Rheumatology Research Foundation Physician-Scientist Development Award, a NIH/NIAMS K08 research grant to study the role of a lipid mediator, lysophosphatidic acid in scleroderma fibrosis, and a Scleroderma Foundation Walter A. Coyle Memorial Research Award.

Departments, Centers, & Programs:

Clinical Interests:



Rheumatology Associates
55 Fruit Street
Boston, MA 02114-2696
Phone: 617-726-7938

Mass General Waltham-Musculoskeletal Ultrasound
52 Second Avenue
Suite 2600
Waltham, MA 02451-1155
Phone: 781-487-6006
Fax: 781-487-4009

Medical Education

  • MD, SUNY at Syracuse (Upstate) College of Medicine
  • SUNY Upstate Medical University at Syracuse, Office of the Registrar
  • Residency, Northwestern Memorial Hospital
  • Fellowship, Massachusetts General Hospital

American Board Certifications

  • Rheumatology, American Board of Internal Medicine
  • Internal Medicine, American Board of Internal Medicine
  • Rheumatology, American Board of Internal Medicine

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Clinical Studies at the MGH Scleroderma Program 

  • Prospective  Registry In Scleroderma at MGH (PRISM)- Database and bio-repository of patients  with scleroderma seen at the MGH Scleroderma Program.
  • The Collaborative, National Quality, and Efficacy Registry (CONQUER) - A collaborative, multi-center database of patients with scleroderma
  • Prospective Registry in Early Systemic Sclerosis (PRESS)- A  collaborative, multi-center database of patients in the early stages of  scleroderma.
  • Ifetroban in Diffuse Systemic Sclerosis or Systemic Sclerosis-Associated Pulmonary Hypertension (Phase II Trial)

For further  information, please contact: Ana Fernandes (adfernandes@mgh.harvard.edu, 617-726-7938)


  • View my most recent publications at PubMed

    Selected Publications: 

    Castelino FV, Dellaripa PF. Recent progress in systemic sclerosis-interstitial lung disease. Curr Op Rheum 2018 Nov;30(6):570-575.

    Schoenfeld SR, Castelino FV. Evaluation & management approaches for scleroderma lung disease. Ther Adv Resp Dis. 2017 Jun 1.

    Castelino FV, Bain G, Pace VA, Black KE, George L, Probst CK, Goulet L, Lafyatis R, Tager AM. An Autotaxin-LPA-IL-6 Amplification Loop Drives Scleroderma Fibrosis. Arthritis Rheum. 2016 Dec;68(12):2964-2974

    Castelino FV, Varga J. Emerging cellular and molecular targets in fibrosis: implications for scleroderma pathogenesis and targeted therapy. Curr Op Rheum 2014 Nov;26(6):607-14

    Castelino FV.  Lipids and Eicosanoids in Fibrosis: Emerging Targets for Therapy.  Curr Op Rheum 2012; 24 (6): 649-655.

    Castelino FV, Goldberg H, Dellaripa PF. The Impact of Rheumatologic Evaluation in the Management of Patients with Interstitial Lung Disease. Rheumatology 2011 Mar;50(3):489-93.

    Castelino FV, Seiders J, Bain G, Brooks SF, King C, Swaney J, Lorrain D, Chun J, Luster AD, Tager AM. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of LPA1 in a mouse model of scleroderma. Arthritis and Rheumatism, 2011. May; 63(5):1405-15.